Peroxisome Proliferator-activated Receptor β/δ Regulates Very Low Density Lipoprotein Production and Catabolism in Mice on a Western Diet
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The results of recent studies using selective agonists for peroxisome proliferator-activated receptor beta (PPARbeta) suggest that this receptor may have a role in regulating levels of serum lipids in animal models of obesity and insulin resistance. To further examine this possibility, serum lipid profiles of mice lacking a functional PPARbeta receptor were determined. PPARbeta-null mice maintained on either normal chow or a 10-week high fat (HF) diet, a condition that has been shown to induce insulin resistance and obesity in mice, have elevated levels of serum triglycerides primarily associated with very low density lipoprotein (VLDL) with no difference in either total cholesterol or phospholipids. Consistent with this finding, PPARbeta-null mice on a HF-diet were shown to have an increased rate of hepatic VLDL production as well as lowered lipoprotein lipase activity in serum compared with wild-type controls. The latter parallels an increase in the hepatic expression of the genes encoding angiopoietin-like proteins 3 and 4 in PPARbeta-null mice on a HF diet, both proteins of which have recently been shown to inhibit lipoprotein lipase (LPL) activity in vivo. Consistent with elevated VLDL production, a marked increase in plasma VLDL apoB48, -E, -AI, and -AII, as well as a sharp depletion of the hepatic lipid stores was also found in PPARbeta-null mice. In addition, PPARbeta-null mice on a HF diet were shown to have increased adiposity, despite lower total body weight. Together, these results indicate a clear role for PPARbeta in regulating levels of serum triglycerides in mice on a high fat Western diet by modulating both VLDL production and LPL-mediated catabolism of VLDL-triglycerides and also suggest a potential therapeutic role for PPARbeta in the improvement of serum lipids in the setting of metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPAR-δ -/-mice showed a reduction in adiposity compared to wild-type animals, which revealed that PPAR-δ is highly involved in the systemic lipid metabolism [143] and regulation of serum/hepatic triglyceride levels [144,145]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [145]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ
Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81574-3 · Cited by 1,860
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Kliewer, S. A., Umesono, K., Mangelsdorf, D. J., & Evans, R. M. (1992) · Nature · doi:10.1038/355446a0 · Cited by 1,489
Research works printed but not linked: 4
- Imai, T., Jiang, M., Chambon, P., and Metzger, D. (2001) Proc. Natl. Acad. Sci.
- Hofmann, C., Lorenz, K., Braithwaite, S. S., Colca, J. R., Palazuk, B. J., Hotamisligil, G. S., and Spiegelman, B. M. (1994) Endocrinology 134, 264 -270 · DOI · Paper page
- Krey, G., Braissant, O., L'Horset, F., Kalkhoven, E., Perroud, M., Parker, M. G., and Wahli, W. (1997) Mol. Endocrinol. 11, 779 -791 · DOI · Paper page
- Iverius, P. H., and Brunzell, J. D. (1985) Am. J. Physiol. 249, E107-E114
Cited by
The Human Obesity Gene Map: The 2005 Update
Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Pérusse, L., & Bouchard, C. (2006) · Obesity · doi:10.1038/oby.2006.71 · Cited by 1,119
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Self-citationPPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
PPARδ regulates glucose metabolism and insulin sensitivity
Lee, C.-H., Olson, P., Hevener, A., Mehl, I., Chong, L.-W., Olefsky, J. M., Gonzalez, F. J., Ham, J., Kang, H., Peters, J. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511253103 · Cited by 497
Self-citationThe Role of Angiopoietin-Like Proteins in Angiogenesis and Metabolism
Hato, T., Tabata, M., & Oike, Y. (2008) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2007.10.003 · Cited by 351
The Human Obesity Gene Map: The 2004 Update
Pérusse, L., Rankinen, T., Zuberi, A., Chagnon, Y. C., Weisnagel, S. J., Argyropoulos, G., Walts, B., Snyder, E. E., & Bouchard, C. (2005) · Obesity Research · doi:10.1038/oby.2005.50 · Cited by 330
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Qiu, Y.-Y., Zhang, J., Zeng, F.-Y., & Zhu, Y. Z. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106786 · Cited by 271
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj062 · Cited by 254
Self-citationThe G0/G1 switch gene 2 is a novel PPAR target gene
Zandbergen, F., Mandard, S., Escher, P., Tan, N. S., Patsouris, D., Jatkoe, T., Rojas-Caro, S., Madore, S., Wahli, W., Tafuri, S., et al. (2005) · Biochemical Journal · doi:10.1042/bj20050636 · Cited by 228
Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road
Desvergne, B., Michalik, L., & Wahli, W. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0088 · Cited by 222
Ehrenborg, E., & Krook, A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001560 · Cited by 213
“However, Ppard knockout mice fed a high-fat diet showed increased adiposity, despite lower total body weight (Akiyama et al., 2004).”
BackgroundThe PPARδ agonist GW0742X reduces atherosclerosis in LDLR−/− mice
Graham, T. L., Mookherjee, C., Suckling, K. E., A. Palmer, C. N., & Patel, L. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.028 · Cited by 201
PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis
Barish, G. D., Atkins, A. R., Downes, M., Olson, P., Chong, L.-W., Nelson, M., Zou, Y., Hwang, H., Kang, H., Curtiss, L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711875105 · Cited by 196
Disruption of CXC Motif Chemokine Ligand-14 in Mice Ameliorates Obesity-induced Insulin Resistance
Nara, N., Nakayama, Y., Okamoto, S., Tamura, H., Kiyono, M., Muraoka, M., Tanaka, K., Taya, C., Shitara, H., Ishii, R., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700412200 · Cited by 176
Koliwad, S. K., Kuo, T., Shipp, L. E., Gray, N. E., Backhed, F., So, A. Y.-L., Farese, R. V., & Wang, J.-C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.025452 · Cited by 164
Barroso, E., Rodríguez-Calvo, R., Serrano-Marco, L., Astudillo, A. M., Balsinde, J., Palomer, X., & Vázquez-Carrera, M. (2011) · Endocrinology · doi:10.1210/en.2010-1468 · Cited by 161
Gervois, P., Fruchart, J.-C., & Staels, B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0397 · Cited by 161
“Triglyceride metabolism is also affected by PPARβ/δ, as shown in PPARβ/δ-deficient mice, which display a hypertriglyceridemic phenotype”
BackgroundDifferential regulation and properties of angiopoietin-like proteins 3 and 4
Ge, H., Cha, J.-Y., Gopal, H., Harp, C., Yu, X., Repa, J. J., & Li, C. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500005-jlr200 · Cited by 135
Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation
Liu, S., Hatano, B., Zhao, M., Yen, C.-C., Kang, K., Reilly, S. M., Gangl, M. R., Gorgun, C., Balschi, J. A., Ntambi, J. M., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.138115 · Cited by 153
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
“In line with the plasma TG-lowering effect of PPARβ/δ agonists observed in primates, plasma TG levels are elevated in PPARβ/δ null mice [98].”
Sanderson, L. M., Boekschoten, M. V., Desvergne, B., Müller, M., & Kersten, S. (2010) · Physiological Genomics · doi:10.1152/physiolgenomics.00127.2009 · Cited by 145
Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy
Oike, Y., Akao, M., Kubota, Y., & Suda, T. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.08.002 · Cited by 155
Peroxisome proliferator-activated receptors, Metabolic Syndrome and Cardiovascular Disease
Azhar, S. (2010) · Future Cardiology · doi:10.2217/fca.10.86 · Cited by 160
Armstrong, E. H., Goswami, D., Griffin, P. R., Noy, N., & Ortlund, E. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.514646 · Cited by 133
Nuclear Receptor Signaling in the Control of Cholesterol Homeostasis: Have the Orphans Found a Home?
Ory, D. S. (2004) · Circulation Research · doi:10.1161/01.res.0000143422.83209.be · Cited by 128
Hamelet, J., Demuth, K., Paul, J., Delabar, J. M., & Janel, N. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.07.028 · Cited by 122
“Recent results also indicate a role for PPARa and PPARd in regulating levels of serum triglycerides in mice by modulating both very low density lipoprotein (VLDL) production and catabolism of VLDL-triglycerides [40,41].”
Morash, A. J., Kajimura, M., & McClelland, G. B. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.02.013 · Cited by 108
Degenhardt, T., Saramäki, A., Malinen, M., Rieck, M., Vaïsänen, S., Huotari, A., Herzig, K., Müller, R., & Carlberg, C. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.06.091 · Cited by 105
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 90
“According to these authors, PPAR / plays a key role in regulating levels of serum triglycerides in high fat fed mice, by modulating both VLDL production and LPL-mediated catabolism of VLDL-triglycerides; this suggests a potential therapeutic role for PPAR / in improving serum lipids of patients with metabolic syndrome…”
BackgroundAngiopoietins and Angiopoietin-Like Proteins in Angiogenesis
Morisada, T., Kubota, Y., Urano, T., Suda, T., & Oike, Y. (2006) · Endothelium · doi:10.1080/10623320600697989 · Cited by 90
Kobayashi, Y., Miyazawa, M., Kamei, A., Abe, K., & KOJIMA, T. (2010) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.100392 · Cited by 102
Kim, D. J., Murray, I. A., Burns, A. M., Gonzalez, F. J., Perdew, G. H., & Peters, J. M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413808200 · Cited by 85
Self-citationIntegrative and Systemic Approaches for Evaluating PPARβ/δ (PPARD) Function
Attianese, G. M. G., & Desvergne, B. (2015) · Nuclear Receptor Signaling · doi:10.1621/nrs.13001 · Cited by 83
“Conversely, PPARβ/δ deficient mice exhibit LDL hypertriglyceridemia, due to increased hepatic production of VLDL and decreased LPL-mediated catabolism [Akiyama et al., 2004].”
BackgroundMatsusue, K., Gavrilova, O., Lambert, G. C., Brewer, H. B., Ward, J. M., Inoue, Y., LeRoith, D., & Gonzalez, F. J. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0213 · Cited by 84
Self-citationEffects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Choi, Y., Roberts, B. K., Wang, X., Geaney, J. C., Naim, S., Wojnoonski, K., Karpf, D. B., & Krauss, R. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.029 · Cited by 80
“Interestingly, hepatic fat content was reduced in this model, perhaps reflecting increased VLDL secretion [26].”
BackgroundBallestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 80
Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors
Mandard, S., Stienstra, R., Escher, P., Tan, N. S., Kim, I., Gonzalez, F. J., Wahli, W., Desvergne, B., Müller, M., & Kersten, S. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7006-1 · Cited by 77
Self-citationTranscriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Tan, N. S., Vázquez‐Carrera, M., Montagner, A., Sng, M. K., Guillou, H., & Wahli, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.001 · Cited by 84
Nuclear Receptors and Inflammatory Diseases
Wang, K., & Wan, Y.-J. Y. (2008) · Experimental Biology and Medicine · doi:10.3181/0708-mr-231 · Cited by 72
Baselga‐Escudero, L., Pascual‐Serrano, A., Ribas‐Latre, A., Casanova, E., Salvadó, M. J., Arola, L., Arola‐Arnal, A., & Bladé, C. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.02.008 · Cited by 77
Takahashi, S., Tanaka, T., Kodama, T., & Sakai, J. (2006) · Pharmacological Research · doi:10.1016/j.phrs.2006.03.019 · Cited by 80
Liaset, B., Hao, Q., Jørgensen, H., Hallenborg, P., Du, Z.-Y., Ma, T., Marschall, H.-U., Kruhøffer, M., Li, R., Li, Q., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.234732 · Cited by 72
Genetics and regulation of angiopoietin-like proteins 3 and 4
Li, C. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000217896.67444.05 · Cited by 70
Triglyceride metabolism and angiopoietin-like proteins in lipoprotein lipase regulation
Li, J., Li, L., Guo, D., Li, S., Zeng, Y., Liu, C., Fu, R., Huang, M., & Xie, W. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.12.029 · Cited by 76
Matsusue, K., Miyoshi, A., Yamano, S., & Gonzalez, F. J. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.05.005 · Cited by 75
“Interestingly, hepatic expression of the genes encoding angiopoietin-like 3 (angptl3) was significantly increased in PPARβ-null mice on a HF diet (Akiyama et al., 2004). angptl3 is a member of a family of secreted growth factors. angptl3-mutant KK/San mice had low levels of plasma lipids (Koishi et…”
BackgroundInfluentialSelf-citationHepatokines—A novel group of exercise factors
Weigert, C., Hoene, M., & Plomgaard, P. (2019) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-018-2216-y · Cited by 57
The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
Huang, T. H.-W., Teoh, A. W., Beilun, L., Lin, D. S.-H., & Roufogalis, B. D. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.03.020 · Cited by 54
Natural PPARs agonists for the treatment of nonalcoholic fatty liver disease
Pan, J., Zhou, W., Xu, R., Xing, L., Ji, G., & Dang, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113127 · Cited by 52
Jones, A., Kulozik, P., Ostertag, A., & Herzig, S. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0973 · Cited by 48
Nie, H., Deng, Y., Zheng, C., Pan, M., Xie, J., Zhang, Y., & Yang, Q. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15166 · Cited by 55
New Therapeutic Target for Metabolic Syndrome: PPAR.DELTA.
Takahashi, S., Tanaka, T., & Sakai, J. (2007) · Endocrine Journal · doi:10.1507/endocrj.kr-99 · Cited by 50
“investigated a lipoprotein metabolism in first generated PPARδ-/- mice lacking the ligand-binding domain of the murine PPARδ gene [11, 23].”
BackgroundNuclear receptors in liver fibrosis
Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45
Genetic Manipulations of PPARs: Effects on Obesity and Metabolic Disease
Barak, Y., & Kim, S. (2007) · PPAR Research · doi:10.1155/2007/12781 · Cited by 41
“increases in hepatic VLDL production, circulating VLDL levels, and VLDL-associated TG in Ppard-null mice [86], this functional interaction suggested that PPARδ is engaged in negative feedback regulation of systemic VLDL flux.”
BackgroundTargeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 49
“In mice, deletion of PPARb/d led to enhanced LDL and triglyceride levels [134].”
BackgroundRepression of glucocorticoid-stimulated angiopoietin-like 4 gene transcription by insulin
Kuo, T., Chen, T.-C., Yan, S. L., Foo, F., Ching, C., McQueen, A., & Wang, J.-C. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m047860 · Cited by 40
Peroxisome proliferator-activated receptor β/δ as a therapeutic target for metabolic diseases
Bedu, E., Wahli, W., & Desvergne, B. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.861 · Cited by 46
Peroxisome proliferator-activated receptor delta and cardiovascular disease
Ehrenborg, E., & Skogsberg, J. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.027 · Cited by 37
Sodhi, R. K., Singh, N., & Jaggi, A. S. (2011) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0654-6 · Cited by 39
“Additionally, they have been implicated in the maintenance of lipid homeostasis (Akiyama et al. 2004), keratinocyte proliferation (Tan et al. 2001) and hyperplasic development of adipose tissue in animals under a high-fat diet (Jehl et al. 2000).”
BackgroundToral, M., Gómez‐Guzmán, M., Jiménez, R., Romero, M., Zarzuelo-Romero, M. J., Utrilla, M. P., Hermenegildo, C., Cogolludo, A. L., Pérez‐Vizcaíno, F., Gálvez, J., et al. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000634 · Cited by 37
Coll, T., Barroso, E., Álvarez-Guardia, D., Serrano, L., Salvadó, L., Merlos, M., Palomer, X., & Vázquez‐Carrera, M. (2010) · PPAR Research · doi:10.1155/2010/368467 · Cited by 38
“Furthermore, deletion of PPARβ/δ in mice led to enhanced LDL and triglyceride levels [94].”
BackgroundZolini, A. M., Block, J., Rabaglino, M. B., Tríbulo, P., Hoelker, M., Rincón, G., Bromfield, J. J., & Hansen, P. J. (2019) · Biology of Reproduction · doi:10.1093/biolre/ioz190 · Cited by 37
Fasting-induced adipose factor/angiopoietin–like protein 4: a potential target for dyslipidemia?
Zandbergen, F., van Dijk, S., Müller, M., & Kersten, S. (2006) · Future Lipidology · doi:10.2217/17460875.1.2.227 · Cited by 29
Fernández, A. Z. (2008) · PPAR Research · doi:10.1155/2008/285842 · Cited by 33
“been implicated in the maintenance of lipid homeostasis [13], keratinocyte proliferation in response to injury [12, 14, 15], hyperplasic development of adipose tissue in animal under a high-fat diet [16], and was recently shown to have beneficial effects on muscle fat oxidation and lipid profiles in humans [17, 18].”
Jiang, B., Liang, P., Zhang, B., Huang, X., & Xiao, X. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.10.051 · Cited by 25
Cloning, chromosome mapping and expression characteristics of porcine ANGPTL3 and -4
Feng, S., Chen, X., Xia, T., Gan, L., Qiu, H., Dai, M. H., Zhou, L., Peng, Y., & Yang, Z. Q. (2006) · Cytogenetic and Genome Research · doi:10.1159/000091927 · Cited by 24
“ANGPTL3 and -4 are activated by various ligands of nuclear receptors, which have important roles in lipid metabolism (Kersten et al., 2000; Yoon et al., 2000; Inaba et al., 2003; Akiyama et al., 2004).”
BackgroundPPARδ agonists and metabolic diseases
Kang, K., Hatano, B., & Lee, C. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693931 · Cited by 27
Hyyti, O. M., & Portman, M. A. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-0643-z · Cited by 21
Pérez‐Schindler, J., Svensson, K., Vargas‐Fernández, E., Santos, G., Wahli, W., & Handschin, C. (2014) · Diabetologia · doi:10.1007/s00125-014-3352-3 · Cited by 19
Karsenty, J., Landrier, J., Rousseau‐Ralliard, D., Masson, V. R., Margotat, A., Deprez, P., Lechêne, P., Grynberg, A., Lairon, D., Planells, R., et al. (2012) · European Journal of Nutrition · doi:10.1007/s00394-012-0488-0 · Cited by 18
Dietary modification of metabolic pathways via nuclear hormone receptors
Caiozzi, G. C., Wong, B. S., & Ricketts, M. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.2842 · Cited by 17
Physiological ligands of PPARs in inflammation and lipid homeostasis
Lathion, C., Michalik, L., & Wahli, W. (2006) · Future Lipidology · doi:10.2217/17460875.1.2.191 · Cited by 12
Finck, B. N. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.2.161 · Cited by 17
Fredrikson, G. N., Lindholm, M., Ljungcrantz, I., Söderberg, I., Shah, P. K., & Nilsson, J. Å. (2007) · Autoimmunity · doi:10.1080/08916930601165107 · Cited by 12
The roles ofPPARsin human diseases
Li, J., & Liu, Y. (2018) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2018.1475673 · Cited by 13
Ham, J., & Kang, H. (2005) · Tetrahedron Letters · doi:10.1016/j.tetlet.2005.07.145 · Cited by 10
Angiopoietin-Like Proteins and Lipid Metabolism
Kersten, S. (2009) · Springer eBooks · doi:10.1007/978-3-642-00300-4_9 · Cited by 10
White adipose tissue browning and peroxisome proliferator activated receptors in MASLD
Li, Z., Chu, H., & Yang, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1667037 · Cited by 11
Barroso, E., Astudillo, A. M., Balsinde, J., & Vázquez‐Carrera, M. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.01.001 · Cited by 8
Peroxisome Proliferator-Activated Receptor β/δ: A novel target for the reduction of atherosclerosis
Gross, B. S., Fruchart, J., & Staels, B. (2005) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2005.08.009 · Cited by 8
Lee, J., & Chung, W. Y. (2011) · Endocrinology · doi:10.1210/en.2011-0211 · Cited by 10
“In PPAR / -null mice, the hypoglyceridemic effect of PPAR / was associated with effects on hepatic VLDL production and clearance (17).”
BackgroundDrug discovery in the metabolic syndrome: context and some recent developments
Suckling, K. E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.801 · Cited by 5
“Mouse knockout studies have shown that PPARδ modulates both VLDL production and lipoprotein lipase-mediated catabolism of VLDL-triglycerides, which suggests a favourable profile in the context of the metabolic syndrome [22].”
BackgroundDevelopment of Synthetic Modulators of PPARs: Current Challenges and Future Opportunities
Pinaire, J. A., Miller, A. R., & Gregoire, F. M. (2008) · PPAR Research · doi:10.1155/2008/786359 · Cited by 4
“Additionally, there is no solid evidence for major changes in renal expression of any of the ENaC subunits in response to PPARγ ligands in vivo [13, 26, 30].”
BackgroundInfluentialPPARs: Important Regulators in Metabolism and Inflammation
Sanderson, L. M., & Kersten, S. (2010) · Springer eBooks · doi:10.1007/978-90-481-3303-1_10 · Cited by 7
“Consistent with these data, plasma TG levels are increased in PPARδ null mice [151].”
BackgroundResultRole of PPARs in the Pathogenesis of the Metabolic Syndrome
Medina‐Gómez, G., Gray, S. L., & Vidal‐Puig, A. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50015-2 · Cited by 3
Zhu, J., Nie, G., Dai, X., Wang, D., Li, S., & Zhang, C. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04450-8 · Cited by 2
Angiopoietin-like protein 4 : an unfolding chaperone regulating lipoprotein lipase activity
Sukonina, V. (2007) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 1
Serra, L. S. (2014) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Barroso, E., Serrano-Marco, L., Salvad, L., Palomer, X., & Vzquez-Carrer, M. (2012) · InTech eBooks · doi:10.5772/27647
“In mice, deletion of PPAR┚/├ led to enhanced LDL and triglyceride levels (Akiyama et al., 2004).”
BackgroundResultInfluentialChapter 3 PPARδ: Emerging therapeutic potential of novel agonists in lipid and glucose homeostasis
Dressel, U., & Muscat, G. E. O. (2006) · Advances in molecular and cellular endocrinology · doi:10.1016/s1569-2566(06)05003-4
Vásquez, Y. (2016) · Cited by 1
Li, S., Nie, G., Dai, X., Zhu, J., Xiao, L., Wang, S., Chen, J., Ren, J., & Zhang, C. (2025) · Poultry Science · doi:10.1016/j.psj.2025.106366
“Some studies pointed out that inhibiting PPAR β / δ led to triglycerides (TG) and FFA accumulation in cells, while activating PPAR β / δ has the opposite effects (Akiyama et al., 2004; Lee et al., 2006).”
Igel, E., Jaeschke, A., Haller, A. M., Asman, M., Mattam, U., Alagarsamy, J., Krishnan, K. C., & Hui, D. Y. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111421
“Increased PPAR transcriptional activities have also been shown to reduce VLDL production (23).”
Liabotis, A. (2018) · theses.fr (ABES) · doi:10.70675/52bcdc87z9aedz40abz9459z9019f91b56fe
Efecte de l'activació de PPARβ/δ sobre l'oxidació d'àcids grassos i el procés inflamatori
Barroso, E. (2011) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
The role of PPARalpha and growth hormone in hepatic lipid metaboism and atherosclerosis
Ljungberg, A. (2006) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Metadata
- Authors
- Akiyama, T. E., Lambert, G., Nicol, C. J., Matsusue, K., Peters, J. M., Brewer, H. B., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 279
- Issue
- 20
- Pages
- 20874-20881
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2112291343
- Cited by
- 97
- References
- 54
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 3 · 2016: 4 · 2015: 3 · 2014: 4 · 2013: 3 · 2012: 4
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5988 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PPARδ, VLDL, VLDL production, VLDL catabolism, lipoprotein lipase, ANGPTL3, ANGPTL4, serum triglycerides, high-fat diet, obesity, insulin resistance, metabolic syndrome, apolipoproteins
- MeSH terms
- Animals, Body Weight, Diet, Dietary Fats, Humans, Lipoproteins, VLDL, Liver, Male, Mice, Inbred C57BL, Organ Size, Reference Values, Transcription Factors, Triglycerides, Blotting, Northern, Receptors, Cytoplasmic and Nuclear, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.